Alpha Cognition Inc
ACOGAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 17, 2026 | H.C. Wainwright | Raghuram Selvaraju | $20.00(+127%) | $8.80 | TheFly |
| Aug 14, 2026 | Craig-Hallum | $17.00(+90%) | $8.94 | TheFly | |
| Jul 10, 2026 | Raymond James | Ryan Deschner | $20.00(+135%) | $8.52 | TheFly |
| May 29, 2026 | Maxim Group | $12.00(+105%) | $5.85 | TheFly | |
| Apr 17, 2026 | Craig-Hallum | $14.00(+111%) | $6.65 | TheFly | |
| Oct 20, 2025 | H.C. Wainwright | $18.00(+165%) | $6.80 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Aug 17, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 22, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 27, 2026 |
| HC Wainwright & Co. | maintain | Buy | Dec 19, 2025 |
| HC Wainwright & Co. | maintain | Buy | Oct 20, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 16, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 1, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 31, 2025 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-0.33| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.40 | $-0.39 | $6.0M | $4.4M |
| May 14, 2026 | $-0.37 | $-0.41 | $3.5M | $3.4M |
| Mar 26, 2026 | $-0.30 | $-0.27 | $2.8M | $3.2M |
| Nov 13, 2025 | $-0.08 | $-0.43 | $2.8M | $2.0M |
| Aug 14, 2025 | $-0.65 | $-0.46 | $1.7M | $4.2M |
| May 15, 2025 | $-0.20 | $-0.58 | $2.9M | $500.0K |
| Mar 31, 2025 | $-0.51 | $-0.48 | — | — |
| Nov 14, 2024 | $-0.31 | $-1.00 | — | — |
News
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company developing and commercializing novel therapeutics for debilitating neurodegenerative disorders, today announced that Michael McFadden, Chief Executive Officer, and Lauren D'Angelo, Chief Operating Officer, will participate in the upcoming investor events: Craig-Hallum Alpha Select Conference Format: 1x1 meetings Date: Tuesday, No.
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its third quarter 2026 financial results and provide a business update on Wednesday, November 11, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its third quarter financial results and business highlights on that date. The financial.
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition" or the "Company"), a biopharmaceutical company developing and commercializing novel therapeutics for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) published U.S. Patent Application No. 19/090,242, titled “Process for Preparing Benzgalantamine and Salts Thereof,” on October 1, 2026, as U.S. Patent Applicatio.
Shares of Alpha Cognition Inc. (NASDAQ: ACOG - Get Free Report) have earned a consensus rating of "Buy" from the five brokerages that are covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have issued a report on the stock
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that new clinical and real-world data on ZUNVEYL and acetylcholinesterase inhibitors will be presented at the American Society of Consultant Pharmacists (ASCP) Annual Meeting, taking place October 29-November 1, 2026 and Neuroscience Education I.
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on October 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 6,000 shares of common stock to a.
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition," "ACI," or the "Company") today announced initial results from CONVERGE, an ongoing retrospective real-world evidence evaluation using longitudinal long-term care medication-administration data. As part of the ongoing CONVERGE evidence-generation program, this analysis focused on 180-day titration and concomitant medication patterns among residents receiving ZUNVEYL (benzgalan.
Karyopharm Therapeutics (NASDAQ: KPTI - Get Free Report) and Alpha Cognition (NASDAQ: ACOG - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations. Analyst Ratings This is a breakdown of
Alpha Cognition Inc. (NASDAQ: ACOG - Get Free Report) has received an average rating of "Buy" from the five analysts that are presently covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have issued ratings on the stock in the last
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on September 8, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 25,000 shares of common stock to.
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on August 31st, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 20,000 shares of common stock to.
Dallas, Texas--(Newsfile Corp. - August 17, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition's 2Q26 strengthens the ZUNVEYL launch setup, with results ahead of prior expectations and demand accelerating despite slower payer implementation.
Alpha Cognition Inc. (ACOG) Q2 2026 Earnings Call Transcript
Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.65 per share a year ago.
Alpha Cognition NASDAQ: ACOG reported second-quarter 2026 net product revenue of approximately $6 million from its Alzheimer's treatment ZUNVEYL, up about 71% sequentially from $3.5 million in the first quarter, as the company cited growing prescriber adoption and deeper use in long-term care facilities.
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a business update. “We are pleased with the continued commercial adoption of ZUNVEYL during the second quarter,” said Michael McFadden, Chief Executive Officer of Alpha.